Compare KMDA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMDA | VNDA |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 474.0M |
| IPO Year | 2013 | 2005 |
| Metric | KMDA | VNDA |
|---|---|---|
| Price | $8.92 | $8.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.00 | ★ $14.90 |
| AVG Volume (30 Days) | 66.6K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $14.79 | $21.50 |
| Revenue Next Year | $11.38 | $38.67 |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $5.54 | $3.81 |
| 52 Week High | $9.35 | $9.60 |
| Indicator | KMDA | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 59.84 |
| Support Level | $6.69 | $4.25 |
| Resistance Level | $9.35 | $9.35 |
| Average True Range (ATR) | 0.27 | 0.56 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 72.63 | 86.31 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.